Innovaderm Research Inc.'s study focuses on developing a non-invasive method to measure mRNA levels in skin samples, which could enhance diagnostic capabilities and therapeutic monitoring for psoriasis and atopic dermatitis. The potential commercialization of this method could position Innovaderm favorably in the dermatology market, particularly as non-invasive diagnostic tools gain traction. The study's completion may attract interest from pharmaceutical companies seeking to integrate biomarker assessments into their clinical trials, thereby enhancing the value proposition of their dermatological products. Competitive implications include the need to monitor similar technologies and methodologies being developed by other entities in the dermatology space.